Article
– Patent valid through 2038 – Phase IIb ALS trial expected to commence H1 2022 Excerpt from the Press Release: CAMBRIDGE, Mass., April 6, 2022 /PRNewswire/ — NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a company developing treatments for severe neurodegenerative diseases, today announced the Canadian Intellectual Property Office has granted the Company a key patent titled “Compositions…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass., April 06, 2022 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced publication in The New England Journal of Medicine (NEJM) of the results from the Phase 3 ADAPT-PO clinical trial for its investigational oral carbapenem antibiotic, tebipenem pivoxil hydrobromide (tebipenem HBr). The paper, titled “Oral Tebipenem Pivoxil Hydrobromide in…
Read More
Low rate of COVID-19 infection observed in vaccinated, durably chimeric patients off immunosuppression No evidence of acute kidney injury or impaired renal function in FCR001-treated patients with COVID-19 infection No patients lost chimerism as a result of COVID-19 vaccination or infection Excerpt from the Press Release: BOSTON and LOUISVILLE, Ky., April 06, 2022 (GLOBE NEWSWIRE) — Talaris Therapeutics,…
Read More
Atreca Announces Licensing Agreement with Zymeworks Atreca Declares EphA2-Targeting ADC (ATRC-301) as Clinical Candidate Virtual R&D Day scheduled for today at 4:15 p.m. EDT Excerpt from the Press Release: SAN CARLOS, Calif., April 05, 2022 (GLOBE NEWSWIRE) — Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a…
Read More
Announcement marks first clinical trial in humans of Ocugen’s modifier gene therapy platform Excerpt from the Press Release: MALVERN, Pa., April 01, 2022 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines, announced that the first patient has been dosed in the Phase 1/2…
Read More
Excerpt from the Press Release: SAN JOSE, Calif., March 30, 2022 /PRNewswire/ — Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced the initiation of a Phase 1 trial evaluating its novel chimeric antigen receptor T-cell (CAR-T) therapy in ovarian cancer. The CAR-T approach used for Anixa’s therapy…
Read More
Data to be Presented During the Emerging Science Session at the American Academy of Neurology’s 74th Annual Meeting The LUMINARY Study is a Phase 2, open-label study evaluating the safety, tolerability and efficacy of SAGE-718 once daily in individuals with mild cognitive impairment and mild dementia due to Alzheimer’s disease SAGE-718 demonstrated improvement across multiple…
Read More Addition of relacorilant to nab-paclitaxel reduces risk of death by 33 percent compared to treatment with nab-paclitaxel alone (p-value: 0.066), without increased side effects Excluding patients (i) who had not responded to even their first treatment with a platinum-based therapy (“primary platinum-refractory” patients) or (ii) who had received four or more prior lines of therapy,…
Read More
CD388 is a drug-Fc conjugate (DFC) from Cidara’s Cloudbreak® platform and is designed to transform the standard of care for seasonal influenza prevention Trial is advancing to dosing subsequent cohorts Initial safety and pharmacokinetics data from study expected in the second half of 2022 Excerpt from the Press Release: SAN DIEGO, March 31, 2022 (GLOBE…
Read More
Results Further Support Clinical Proof-of-Concept for CRN04777 by Showing Dose-Dependent Decreases in Fasting and Sulfonylurea-Induced Insulin Secretion Management Hosting Webcast and Conference Call to Discuss Findings Today at 4:30 p.m. Eastern Time Excerpt from the Press Release: SAN DIEGO – March 30, 2022 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused…
Read More